Antibody Therapy of Acute and Chronic Leukemias

Authors: Cataland S.R.; Lucas M.; Byrd J.C.

Source: Current Pharmaceutical Biotechnology, Volume 2, Number 4, December 2001 , pp. 357-367(11)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The development of antibody-based therapies for the treatment of both acute and chronic leukemias have undoubtedly been one of the most important advances in the treatment of leukemia. The importance of these novel agents lies not only in their unique mechanisms of action, but also their improved side effect profile which allows patients of advanced age or with significant co-morbid medical conditions to receive potentially beneficial therapies. Advances in therapeutic applications of monoclonal antibodies have come from a greater understanding of the biological characteristics of the antibody, as well as the target antigen, both of which impact the potential efficacy of a particular antibody. In the following review we will discuss the clinical development and potential roles of monoclonal antibodies in the treatment of both acute and chronic leukemias.

Keywords: Chronic Leukemias; monoclonal antibodies; RITUXIMAB IN CLL; CAMPATH-1H; GEMTUZAMB OZOGAMICIN

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201013378608

Publication date: 2001-12-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.